Ryoncil® Product Information Listed in Major Drug Compendia
Mesoblast Limited, a pioneer in allogeneic cellular medicines, recently shared exciting news regarding its innovative product, Ryoncil®. This product is now included in all four major drug pricing compendia in the United States. These comprehensive sources are essential for healthcare providers as they provide critical information needed for ordering the product, including manufacturing details, National Drug Codes (NDC) for purchasing, and kit pricing.
Understanding the Importance of Pricing Compendia
The inclusion of Ryoncil® in the pricing compendia comes after approval and updates by the U.S. Food and Drug Administration (FDA). The revised label encompasses significant changes, particularly in Section 16, concerning the supply, storage, and handling of the product. Among these updates, eight new kits were launched, each designated with unique NDCs. This tailored approach enables treatment centers to order kits that match the specific dosages required for their patients, ensuring a uniform pricing application irrespective of patient weight.
Components of the Drug Pricing Compendia
The four primary compendia that now list Ryoncil® include Merative Micromedex® RED BOOK®, First Databank FDB MedKnowledge® Drug Pricing, Elsevier Gold Standard Drug Database, and Wolters Kluwer Medi-Span® Price Rx®. Healthcare professionals utilize these compendia for accurate and up-to-date pricing information, which ultimately supports better treatment outcomes.
About Mesoblast Limited
Mesoblast Limited stands out as a leading entity in the field of allogeneic cellular therapies, focusing on treatments for severe inflammatory diseases. Their proprietary mesenchymal lineage cell therapy platform is remarkably effective in addressing severe inflammation by releasing anti-inflammatory factors. This innovative technology has shown the capability to modulate the immune system effectively, leading to a significant decrease in harmful inflammatory processes.
The Role of Ryoncil® in Treating SR-aGvHD
Ryoncil® (remestemcel-L) is specifically designed to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older. Being the first FDA-approved mesenchymal stromal cell (MSC) therapy, it brings hope to many vulnerable individuals. For further details, including comprehensive prescribing information, healthcare providers can visit Ryoncil’s dedicated website.
Future Developments and Commitments
Mesoblast is continuously innovating, working on additional cell therapies intended for specific medical indications using both remestemcel-L and another potential therapy, rexlemestrocel-L. Ryoncil® is concurrently being researched for various inflammatory conditions, including SR-aGvHD in adults as well as biologic-resistant inflammatory bowel disease. On the other hand, the rexlemestrocel-L treatment is directed towards managing heart failure and chronic low back pain. As part of its growth strategy, Mesoblast has established several commercial partnerships across Japan, Europe, and China.
Intellectual Property and Manufacturing Strengths
In addition to their therapeutic advancements, Mesoblast boasts a robust global intellectual property portfolio. With over 1,000 patents granted or pending, they ensure comprehensive protection surrounding their mesenchymal stromal cell compositions, methods of manufacture, and treatment indications. This intellectual capital is expected to shield their innovations in key markets until at least 2041.
The manufacturing capabilities of Mesoblast are equally impressive. Utilizing proprietary processes, they produce cryopreserved, industrial-scale cellular medicines, which are designed to be widely accessible to patients around the globe. The defined pharmaceutical release criteria ensure that these therapies meet high-quality standards.
Global Presence and Future Vision
With operational bases in Australia, the United States, and Singapore, Mesoblast Limited is well-positioned to expand its reach and impact in the global healthcare landscape. Along with its listings on the Australian Securities Exchange (MSB) and Nasdaq (MESO), the company continues to enhance its visibility and operational efficiency in pursuit of innovative healthcare solutions.
Frequently Asked Questions
What is Ryoncil® and what condition does it treat?
Ryoncil® (remestemcel-L) is an FDA-approved therapy designed to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.
How does the inclusion in drug pricing compendia benefit healthcare providers?
The inclusion of Ryoncil® in major drug pricing compendia provides healthcare providers with critical information about ordering, pricing, and patient-specific dosage options, facilitating more informed treatment decisions.
What is Mesoblast’s approach to developing new therapies?
Mesoblast is dedicated to advancing allogeneic cellular therapies for various inflammatory conditions, continuously researching and developing new products based on their innovative technology platforms.
How many patents does Mesoblast hold for its technologies?
Mesoblast has an extensive portfolio with over 1,000 granted patents and pending applications, ensuring substantial protection for its innovative therapies and processes.
Where can more information about Ryoncil® and Mesoblast be found?
Healthcare providers and interested parties can find detailed information about Ryoncil® and Mesoblast’s other products on their official website and company resources.
